← Eichor
Condition: Advanced Extrapulmonary Neuroendocrine Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Extrapulmonary Neuroendocrine Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus C
Phase 3 · 165 location(s) · Boehringer Ingelheim · NCT07544654Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Phase 1 · 20 location(s) · SystImmune Inc. · NCT07080242Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients
Phase 2 · 4 location(s) · Inkeun Park · NCT06893783Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcino
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07518602
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.